Satraplatin
- CAS No.
- 129580-63-8
- Chemical Name:
- Satraplatin
- Synonyms
- JM 216;C081294;BMY 45594;BMS 182751;SATRAPLATIN;Satraplatin(JM216);BMS-182751;BMY-45594;JM-216;bis(acetato-o)amminedichloro(cyclohexanamine)-pt;Bis-acetatoamminedichlorocyclohexylamine platinum(iv);(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
- CBNumber:
- CB2675796
- Molecular Formula:
- C10H20Cl2N2O4Pt
- Molecular Weight:
- 498.26
- MOL File:
- 129580-63-8.mol
- Modify Date:
- 2024/7/2 8:55:04
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Toxicity | LD50 in mice (mg/kg): 30 i.p.; 330 orally (Kelland) | |||||||||
| NFPA 704 |
|
Satraplatin Chemical Properties,Uses,Production
Uses
Antineoplastic.
Definition
ChEBI: A platinum coordination entity that consists of a central platunum atom bound to chloro (x2), acetate (x2), amino, and cyclohexylamino groups. Used for treatment of advanced prostate cancer.
Pharmaceutical Applications
Satraplatin (JM216, cis,trans,cis-[PtCl2(OAc)2(NH3)(C6H5NH2)]) is a Pt(IV) or Pt4+ complex, which is
active by oral administration, as it is more hydrophobic than cisplatin. This form of administration is very
attractive because of the convenience and freedom it provides to the patient. Satraplatin also has a milder toxicity
profile and is shows no cross-resistance with cisplatin. Satraplatin in combination with prednisone has
completed phase III clinical trials against hormone-refractory prostate cancer. The results were very encouraging,
but the overall survival rate did not improve significantly enough. As a result, the fast-track approval
of the FDA was not granted.
Structurally, satraplatin consists of a Pt(IV) centre, which is coordinated by six ligands forming a close to octahedral geometry. In general, octahedral Pt(IV) complexes (low-spin d6) are much more kinetically inert than square planar Pt(II) complexes.
Clinical Use
This newest organometallic agent currently is in clinical trials as a second-line agent for the treatment of hormone-refractory prostate cancer . There is hope that it also will find value in ovarian cancer and small cell lung cancer.
Side effects
As with other organoplatinum complexes, the diaquo form is active. At this early stage, the toxicity profile appears to be mild, with dose-related myelosuppression, particularly neutropenia and thrombocytopenia, being the major use-limiting side effect.
Metabolism
Unlike the square-planar Pt(II) complexes currently on the market, it is active by the oral route. It is metabolized quickly in whole blood, producing up to six metabolites. The major metabolite is the desacetoxy analogue.
Satraplatin Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29898 | 58 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | China | 39916 | 58 | Inquiry |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | China | 49391 | 58 | Inquiry |
| SIMAGCHEM CORP | +86-13806087780 | China | 17367 | 58 | Inquiry |
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | China | 15395 | 58 | Inquiry |
| Finetech Industry Limited | +86-27-87465837 +8618971612321 | China | 9618 | 58 | Inquiry |
| Wuhan Fortuna Chemical Co., Ltd | +86-027-59207850 | China | 5988 | 58 | Inquiry |
| Dayang Chem (Hangzhou) Co.,Ltd. | 571-88938639 +8617705817739 | China | 52861 | 58 | Inquiry |
129580-63-8(Satraplatin)Related Search:
1of4
chevron_right